Cutera Announces Second Quarter 2023 Financial Results along with 2023 Outlook

Rhea-AI Summary

Cutera, Inc. reports financial results for Q2 2023, with a decrease in revenue and gross margin compared to the prior-year period. AviClear new bookings decline in line with strategy. GAAP net loss improves. CEO acknowledges operational and market challenges and expresses confidence in the company's potential.

Positive

• AviClear Q2 2023 new bookings decline in line with strategy
• GAAP net loss improves

Negative

• Consolidated revenue decreases by 5%
• GAAP gross margin decreases from 54.6% to 45.8%
• Operating expenses increase from $45.1 million to $57.6 million
• Adjusted EBITDA is a loss of $11.6 million

BRISBANE, Calif.--(BUSINESS WIRE)-- Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2023.

Second Quarter 2023 Financial and Operational Highlights

• Consolidated revenue of $61.2 million, a decrease of 5% as reported and a decrease of 2% in constant currency from the prior-year period, primarily driven by a decline in capital equipment revenue, partially offset by AviClear revenue.
• AviClear Q2 2023 new bookings of just under 200 units, vs. over 350 in Q1 2023, in line with our strategy to drive a more measured pace of new bookings.
• GAAP Gross margin of 45.8% in the quarter, compared to 54.6% in the prior-year period.
• Non-GAAP Gross margin of 50.3% in the quarter, compared to 55.6% in the prior-year period.
• GAAP Operating expenses were $57.6 million in the quarter, compared to $45.1 million in the prior-year period. Operating expenses during the period included $10.6 million in AviClear spending, up $3.6 million from the prior-year period.
• GAAP Net loss was $31.6 million, compared to a GAAP Net loss of $47.3 million in the prior-year period.
• Adjusted EBITDA was a loss of $11.6 million, compared to a loss of $1.6 million in the prior-year period.
  • Core adjusted EBITDA was a loss of $4.3 million.
  • AviClear adjusted EBITDA was a loss of $7.3 million.

	Three Months Ended June 30, 2023	% Change vs Three Months Ended June 30, 2022				Three Months Ended June 30, 2023
Key Revenue Metrics		Reported	Constant Currency		Key Profit Metrics
Capital Equipment	$37.9	-13%	-11%		GAAP Margin %	45.8%
Skincare	$9.4	-2%	5%		Non-GAAP Margin %	50.3%
Consumables	$4.3	-18%	-16%		Adjusted EBITDA - Core	($4.3)
Service	$5.7	0%	2%		Adjusted EBITDA - AviClear	($7.3)
AviClear	$4.0	nm	nm		Adjusted EBITDA - Total	($11.6)
Recurring	$23.3	13%	18%		Adjusted EBITDA Margin %	-19.0%
Total Revenue	$61.2	-5%	-2%
	Six Months Ended June 30, 2023	% Change vs Six Months Ended June 30, 2022				Six Months Ended June 30, 2023
Key Revenue Metrics		Reported	Constant Currency		Key Profit Metrics
Capital Equipment	$71.2	-11%	-9%		GAAP Margin %	45.6%
Skincare	$17.6	-18%	-8%		Non-GAAP Margin %	49.7%
Consumables	$8.0	-12%	-9%		Adjusted EBITDA - Core	($12.9)
Service	$11.1	-5%	-2%		Adjusted EBITDA - AviClear	($13.3)
AviClear	$8.4	nm	nm		Adjusted EBITDA - Total	($26.1)
Recurring	$45.0	7%	13%		Adjusted EBITDA Margin %	-22.5%
Total Revenue	$116.2	-5%	-1%

“Second quarter results reflect that our business faces more operational and market challenges than were apparent when I stepped in as interim CEO. While we succeeded in refocusing our selling organization on Core Capital, business performance in this area has been negatively impacted by continued parts-driven service delays, and a tightening credit environment which have made deal closing more difficult, and placed pressure on our ASP’s. Addressing these challenges is a top priority for the company and we are working diligently to get Core Capital back on track,” commented Sheila Hopkins, former interim Chief Executive Officer of Cutera Inc.

Hopkins continued, “On AviClear we have more work to do to increase utilization and the percent of installed offices that are contributing. We are working expeditiously on the playbook for that. This will be a process; however, I am encouraged by progress made in the quarter on AviClear. We moved forward with a more measured pace of device bookings, and drove treatment volume that was in-line with our expectations. Finally, AviClear became the first acne therapy to obtain FDA clearance as a long-term treatment for mild to severe acne vulgaris.”

“I continue to believe in the potential of Cutera, fueled by excellent technologies, and a dedicated and talented team. The challenges before us can and will be addressed, particularly with Taylor at the helm given his deep industry experience. This will place the Company firmly on the path to unlock inherent upside value not only on AviClear, but also Core Capital. Cutera’s future remains bright,” concluded Hopkins.

“I am very excited about the platform, the team, and the opportunity ahead at Cutera. While we face a set of near-term challenges, which our team will address, we have significant potential to drive growth and profitability over time, not only with our AviClear, our revolutionary solution for acne, but across our entire portfolio,” commented Taylor Harris, Chief Executive Officer of Cutera, Inc.

2023 Outlook

The company expects full-year 2023 revenue in the range of $220 million to $230 million.

Conference Call

The Company’s management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Taylor Harris, Chief Executive Officer; Sheila Hopkins, former Interim Chief Executive Officer; Stuart Drummond, Interim Chief Financial Officer; and Greg Barker, Vice President of FP&A and Investor Relations.

To participate in the conference call, dial 1-800-319-4610 (domestic) or +1-631-891-4304 (international).

The call will also be a webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.

*Use of Non-GAAP Financial Measures

In this press release, to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for gross margin, gross margin rate, and operating income. Non-GAAP adjustments include depreciation and amortization including contract acquisition costs, stock-based compensation, enterprise resource planning (“ERP”) implementation costs, certain legal and litigation costs, executive and other non-recurring severance costs, costs related to a retention plan, and legal and advisory fees related to litigation and shareholder activism. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.

The Company defines adjusted EBITDA as operating income before depreciation and amortization, stock-based compensation, ERP implementation costs, costs related to certain litigation, executive and non-recurring severance costs, retention plan costs, and legal and advisory fees related to litigation and shareholder activism.

Company management uses non-GAAP measures as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:

Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations.

Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies.

ERP implementation costs. The Company has excluded ERP system costs related to direct and incremental costs incurred in connection with its multi-phase implementation of a new ERP solution and the related technology infrastructure costs. The Company excludes these costs because it believes that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of the Company’s operating performance.

Certain legal and litigation costs. The Company has excluded costs incurred related to its litigation against Lutronic Aesthetics, which is not part of the Company’s ordinary course of business. The Company’s complaint against Lutronic alleges misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), interference with contractual relations and other claims. The Company excludes these costs because this litigation is a result of a discrete event that was not part of the Company’s business strategy, but has a significant effect on the results of operations. Its costs are incidental to and do not reflect the efficiencies and effectiveness of the Company’s core operations.

Executive and other non-recurring severance costs. The Company has excluded costs associated with restructuring activities and the separation of its officers and other executives in calculating its non-GAAP operating expenses and non-GAAP Operating Income. The Company has excluded restructuring costs because a restructuring represents a discrete event that signifies a change in the Company’s strategy, but its costs are not indicative of the ongoing financial performance of the business. The Company excludes executive separation costs because executive separations are unpredictable and not part of the Company’s business strategy but could have a significant impact on the results of operation.

Retention plan costs. The Company has excluded the expense related to a retention plan implemented in April 2023. Approximately $11 million was made available to sales personnel and key employees and will be paid in quarterly installments through October 2024. The Company has excluded expense related to this retention plan as such costs are not considered part of ongoing operations.

Board of Director legal and advisory fees. The Company has excluded costs associated with the litigation and shareholder activism related to its 2023 annual meeting of shareholders. The Company has excluded these costs as the costs do not relate to ongoing operations.

The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include but are not limited to, Cutera’s plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

All information in this press release is as of the date of its release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the second quarter ended June 30, 2023, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

CUTERA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
			June 30,				December 31,
				2023				2022
Assets
Current assets:
	Cash and cash equivalents		$	180,654			$	145,924
	Marketable investments			41,949				171,390
	Accounts receivable, net			53,079				45,562
	Inventories, net			68,668				63,628
	Other current assets and prepaid expenses			24,900				24,036
	Restricted cash			700				700
		Total current assets		369,950				451,240
Property and equipment, net				65,511				40,368
Deferred tax asset				547				590
Goodwill				1,339				1,339
Operating lease right-of-use assets				11,370				12,831
Other long-term assets				15,113				14,620
		Total assets	$	463,830			$	520,988
Liabilities and Stockholders' Deficit
Current liabilities:
	Accounts payable		$	34,240			$	33,736
	Accrued liabilities			53,764				57,452
	Operating leases liabilities			2,602				2,810
	Deferred revenue			12,457				11,841
		Total current liabilities		103,063				105,839
Deferred revenue, net of current portion				1,690				1,657
Operating lease liabilities, net of current portion				10,069				11,352
Convertible notes, net of unamortized debt issuance costs				417,568				416,459
Other long-term liabilities				575				862
		Total liabilities		532,965				536,169
Stockholders’ deficit:
	Common stock			20				20
	Additional paid-in capital			128,014				125,406
	Accumulated other comprehensive income (loss)			4				(94	)
	Accumulated deficit			(197,173	)			(140,513	)
		Total stockholders' deficit		(69,135	)			(15,181	)
		Total liabilities and stockholders' deficit	$	463,830			$	520,988

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
	Three Months Ended								Six Months Ended
	June 30,				June 30,				June 30,				June 30,
	2023				2022				2023				2022
Products	$	55,568			$	58,589			$	105,156			$	110,655
Service		5,650				5,635				11,055				11,583
Total net revenue		61,218				64,224				116,211				122,238
Products		29,473				25,899				56,704				48,811
Service		3,691				3,281				6,526				6,595
Total cost of revenue		33,164				29,180				63,230				55,406
Gross profit		28,054				35,044				52,981				66,832
Gross margin %		45.8	%			54.6	%			45.6	%			54.7	%
Operating expenses:
Sales and marketing		33,271				27,001				62,783				51,945
Research and development		5,784				6,859				12,252				13,358
General and administrative		18,528				11,248				31,044				24,750
Total operating expenses		57,583				45,108				106,079				90,053
Loss from operations		(29,529	)			(10,064	)			(53,098	)			(23,221	)
Amortization of debt issuance costs		(557	)			(298	)			(1,109	)			(517	)
Interest on convertible notes		(2,958	)			(1,149	)			(5,897	)			(1,927	)
Loss on extinguishment of convertible notes		-				(34,423	)			-				(34,423	)
Interest income		2,179				382				4,658				395
Other expense, net		(453	)			(1,910	)			(616	)			(2,678	)
Loss before income taxes		(31,318	)			(47,462	)			(56,062	)			(62,371	)
Income tax expense (benefit)		326				(186	)			598				47
Net loss	$	(31,644	)		$	(47,276	)			(56,660	)		$	(62,418	)
Net loss per share:
Basic	$	(1.59	)		$	(2.53	)			(2.86	)		$	(3.39	)
Diluted	$	(1.59	)		$	(2.53	)			(2.86	)		$	(3.39	)
Weighted-average number of shares used in per share calculations:
Basic		19,858				18,700				19,819				18,392
Diluted		19,858				18,700				19,819				18,392

CUTERA, INC.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in thousands, except percentage data)
(unaudited)
				Three Months Ended								% Change			Six Months Ended								% Change
				June 30,				June 30,				2023 Vs			June 30,				June 30,				2023 Vs
				2023				2022				2022			2023				2022				2022
Revenue By Geography:
		North America		$	31,830			$	32,239			-1.3	%		$	59,499			$	61,092			-2.6	%
		Japan			12,810				15,174			-15.6	%			25,718				32,677			-21.3	%
		Rest of World			16,578				16,811			-1.4	%			30,994				28,469			+8.9%
		Total Net Revenue		$	61,218			$	64,224			-4.7	%		$	116,211			$	122,238			-4.9	%
		International as a percentage of total revenue			48.0	%			49.8	%						48.8	%			50.0	%
Revenue By Product Category:
	Systems
		- North America		$	22,243			$	25,232			-11.8	%		$	40,203			$	47,939			-16.1	%
		- Rest of World (including Japan)			15,652				18,421			-15.0	%			31,010				32,228			-3.8	%
		Total Systems			37,895				43,653			-13.2	%			71,213				80,167			-11.2	%
	AviClear				3,996				136			nm				8,391				136			nm
	Consumables				4,255				5,162			-17.6	%			7,998				9,065			-11.8	%
	Skincare				9,422				9,638			-2.2	%			17,554				21,287			-17.5	%
		Total Products			55,568				58,589			-5.2	%			105,156				110,655			-5.0	%
	Service				5,650				5,635			+0.3%				11,055				11,583			-4.6	%
		Total Net Revenue		$	61,218			$	64,224			-4.7	%		$	116,211			$	122,238			-4.9	%

				Three Months Ended								Six Months Ended
				June 30,				June 30,				June 30,				June 30,
				2023				2022				2023				2022
Pre-tax Stock-Based Compensation Expense:
		Cost of revenue		$	361			$	500			$	725			$	959
		Sales and marketing			1,283				1,638				2,431				2,214
		Research and development			415				1,067				1,108				2,047
		General and administrative			(509	)			1,528				672				3,556
				$	1,550			$	4,733			$	4,936			$	8,776

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
			Three Months Ended								Six Months Ended
			June 30,				June 30,				June 30,				June 30,
				2023				2022				2023				2022
Cash flows from operating activities:
Net loss			$	(31,644	)		$	(47,276	)		$	(56,660	)		$	(62,418	)
Adjustments to reconcile net loss to net cash provided used in operating activities:				-
	Stock-based compensation			1,550				4,733				4,936				8,776
	Depreciation and amortization			1,829				502				3,238				929
	Amortization of contract acquisition costs			1,891				567				4,069				1,219
	Amortization of debt issuance costs			557				298				1,109				517
	Deferred tax assets			30				39				43				80
	Provision for credit losses			2,026				217				2,514				409
	Loss on sale of property and equipment			-				49				-				63
	Loss on extinguishment of convertible notes			-				34,423				-				34,423
	Unrealized gain on foreign exchange forward			623				-				-				-
	Non-cash interest income			(1,115	)			-				(1,995	)			-
Changes in assets and liabilities:				-
	Accounts receivable			(2,967	)			804				(10,031	)			(1,108	)
	Inventories, net			3,151				(5,324	)			(5,040	)			(17,501	)
	Other current assets and prepaid expenses			1,175				2,577				(878	)			(3,034	)
	Other long-term assets			(2,771	)			(686	)			(4,782	)			(1,071	)
	Accounts payable			(336	)			9,016				(1,666	)			14,771
	Accrued liabilities			(5,512	)			(889	)			(3,806	)			(6,878	)
	Operating leases ,net			(14	)			6				(30	)			36
	Deferred revenue			261				463				649				702
		Net cash used in operating activities		(31,266	)			(481	)			(68,330	)			(30,085	)
Cash flows from investing activities:
Acquisition of property and equipment				(14,755	)			(7,917	)			(25,908	)			(8,238	)
Purchase of marketable investments				-				(129,251	)			(23,467	)			(203,309	)
Proceeds from maturities of marketable investments				60,000				-				155,000				-
		Net provided by (used in) cash used in investing activities		45,245				(137,168	)			105,625				(211,547	)
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan				749				1,288				858				1,440
Purchase of capped call				-				(31,671	)			-				(31,671	)
Proceeds from issuance of convertible notes				-				240,000				-				240,000
Payment of issuance costs of convertible notes				-				(6,956	)			-				(6,956	)
Extinguishment of convertible notes				-				(45,777	)			-				(45,777	)
Taxes paid related to net share settlement of equity awards				(789	)			(1,784	)			(3,186	)			(4,234	)
Payments on finance lease obligation				(113	)			(133	)			(237	)			(284	)
		Net cash provided by (used in) financing activities		(153	)			154,967				(2,565	)			152,518
Net increase (decrease) in cash, cash equivalents and restricted cash				13,826				17,318				34,730				(89,114	)
Cash, cash equivalents, and restricted cash at beginning of period				167,528				58,432				146,624				164,864
Cash, cash equivalents, and restricted cash at end of period			$	181,354			$	75,750			$	181,354			$	75,750

CUTERA, INC. Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (in thousands) (unaudited)
Three Months Ended June 30, 2023				Gross Profit				Gross Margin			Operating Income
Reported				$	28,054			45.8	%		$	(29,529	)
Adjustments:
	Depreciation and amortization including contract acquisition costs				1,998			3.3	%			3,991
	Stock-based compensation				361			0.6	%			1,550
	ERP implementation costs				-			-				770
	Legal				-			-				394
	Severance				-			-				234
	Retention plan costs				65			0.1	%			2,972
	Board of Director legal and advisory fees				-			-				7,709
	Other adjustments				307			0.5	%			307
		Total adjustments			2,731			4.5	%			17,927
Adjusted				$	30,785			50.3	%		$	(11,602	)
Three Months Ended June 30, 2022				Gross Profit				Gross Margin			Operating Income
Reported				$	35,044			54.6	%		$	(10,064	)
Adjustments:
	Depreciation and amortization including contract acquisition costs				161			0.3	%			1,068
	Stock-based compensation				500			0.8	%			4,733
	ERP implementation costs				-			-				2,385
	Legal				-			-				242
	Severance				-			-				-
	Other adjustments				-			-				-
		Total adjustments			661			1.0	%			8,428
Adjusted				$	35,705			55.6	%		$	(1,636	)

Six Months Ended June 30, 2023			Gross Profit				Gross Margin			Operating Income
Reported			$	52,981			45.6	%		$	(53,098	)
Adjustments:
	Depreciation and amortization including contract acquisition costs			3,597			3.1	%			7,578
	Stock-based compensation			725			0.6	%			4,936
	ERP implementation costs			-			-				1,288
	Legal			-			-				1,046
	Severance			119			0.1	%			549
	Retention plan costs			65			0.1	%			2,972
	Board of Director legal and advisory fees			-			-				7,709
	Other adjustments			307			0.3	%			892
	Total adjustments			4,813			4.1	%			26,970
Adjusted			$	57,794			49.7	%		$	(26,128	)
Six Months Ended June 30, 2022			Gross Profit				Gross Margin			Operating Income
Reported			$	66,832			54.7	%		$	(23,221	)
Adjustments:
	Depreciation and amortization including contract acquisition costs			237			0.2	%			2,147
	Stock-based compensation			959			0.8	%			8,776
	ERP implementation costs			-			-				6,361
	Legal			-			-				496
	Severance			-			-				-
	Other adjustments			-			-				-
	Total adjustments			1,196			1.0	%			17,780
Adjusted			$	68,028			55.7	%		$	(5,441	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230808834483/en/

Cutera, Inc.

Greg Barker

VP, Corporate FP&A and Investor Relations

415-657-5500

IR@cutera.com

Source: Cutera, Inc.

FAQ

What is the revenue for Q2 2023?

The revenue for Q2 2023 is $61.2 million.

What is the GAAP gross margin for the quarter?

The GAAP gross margin for the quarter is 45.8%.

What is the GAAP net loss for the quarter?

The GAAP net loss for the quarter is $31.6 million.

What is the adjusted EBITDA for the quarter?

The adjusted EBITDA for the quarter is a loss of $11.6 million.

What is the outlook for full-year 2023 revenue?

The company expects full-year 2023 revenue in the range of $220 million to $230 million.